E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modifications, whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeruva, Sri Lakshmi Hyndavi, Zhao, Fengmin, Miller, Kathy D., Tevaarwerk, Amye J., Wagner, Lynne I., Gray, Robert J., Sparano, Joseph A., Connolly, Roisin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765007/
https://www.ncbi.nlm.nih.gov/pubmed/29354686
http://dx.doi.org/10.1038/s41523-017-0053-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765007/
https://www.ncbi.nlm.nih.gov/pubmed/29354686
http://dx.doi.org/10.1038/s41523-017-0053-3

Ejemplares similares